Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study

Epilepsia partialis continua (EPC) is a rare and challenging form of focal motor status epilepticus. Its occurrence strictly in systemic autoimmune disorders without overt encephalitis is exceptional. Corticosteroids are first-line therapy but may be limited by significant side effects and poor metabolic tolerability. We report a 54-year-old woman with Autoimmune Polyendocrine Syndrome (APS), including autoimmune hepatitis, latent autoimmune diabetes in adults, celiac disease, and hypothyroidism, presenting with continuous jerks of right III-V fingers. Neurological examination showed continuous, irregular jerks confined to the right III, IV, and V fingers. Extensive serum and CSF screenings, including neuronal antibodies, and MRI were unremarkable. Ictal HMPAO-SPECT revealed a focal hyperperfusion in the left hand-knob area of the primary motor cortex. Brain FDG-PET revealed focal hypometabolism in the same region. Video-EEG-EMG polygraphy showed intermittent spikes and polyspikes over the left central region preceding EMG bursts of the right V finger's abductor muscle with a latency of approximately 30-40 ms. These findings were consistent with EPC. Corticosteroids induced marked improvement but were discontinued due to severe glycemic worsening. Subsequent treatment with oral steroids, IVIG, and multiple antiseizure medications were ineffective. Administration of Rituximab led to complete and sustained clinical and electrophysiological remission, which persisted at the 18-month follow-up. EPC can be a severe, focal manifestation of systemic autoimmunity even without encephalitis. Rituximab represents an effective steroid-sparing option for refractory autoimmune EPC, particularly in metabolically vulnerable patients.

Authors

Institutions

Publication Details

Journal
Epileptic Disorders
Published
2026-11-20
DOI
https://doi.org/10.1002/epd2.70481
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study

Gudrun Kalss, Angelo Pascarella, Fabio Rossini, Markus Leitinger et al.
Epileptic Disorders
Epilepsy research and treatment
article

Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study

Gudrun Kalss, Angelo Pascarella, Fabio Rossini, Markus Leitinger, Eugen Trinka, Giorgi Kuchukhidze, Chiara Ferrazzoli
article en

Abstract

Epilepsia partialis continua (EPC) is a rare and challenging form of focal motor status epilepticus. Its occurrence strictly in systemic autoimmune disorders without overt encephalitis is exceptional. Corticosteroids are first-line therapy but may be limited by significant side effects and poor metabolic tolerability. We report a 54-year-old woman with Autoimmune Polyendocrine Syndrome (APS), including autoimmune hepatitis, latent autoimmune diabetes in adults, celiac disease, and hypothyroidism, presenting with continuous jerks of right III-V fingers. Neurological examination showed continuous, irregular jerks confined to the right III, IV, and V fingers. Extensive serum and CSF screenings, including neuronal antibodies, and MRI were unremarkable. Ictal HMPAO-SPECT revealed a focal hyperperfusion in the left hand-knob area of the primary motor cortex. Brain FDG-PET revealed focal hypometabolism in the same region. Video-EEG-EMG polygraphy showed intermittent spikes and polyspikes over the left central region preceding EMG bursts of the right V finger's abductor muscle with a latency of approximately 30-40 ms. These findings were consistent with EPC. Corticosteroids induced marked improvement but were discontinued due to severe glycemic worsening. Subsequent treatment with oral steroids, IVIG, and multiple antiseizure medications were ineffective. Administration of Rituximab led to complete and sustained clinical and electrophysiological remission, which persisted at the 18-month follow-up. EPC can be a severe, focal manifestation of systemic autoimmunity even without encephalitis. Rituximab represents an effective steroid-sparing option for refractory autoimmune EPC, particularly in metabolically vulnerable patients.

Epileptic Disorders
University of Rome Tor Vergata (IT), Paracelsus Medical University (AT), Magna Graecia University (IT), Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT), Christian Doppler Klinik (AT), UMIT - Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik (AT)
Good health and well-being
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Rituximab‐responsive epilepsia partialis continua in autoimmune Polyendocrine syndrome: A video‐ EEG – EMG polygraphic study — Gudrun Kalss, Angelo Pascarella, et al. · Epileptic Disorders (2026) | TGRS Research Map | TGRS